INT229111

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 1.12
Pain Relevance 2.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (SLC6A3) cell death (SLC6A3) aging (SLC6A3)
plasma membrane (SLC6A3) transmembrane transport (SLC6A3) cytoplasm (SLC6A3)
Anatomy Link Frequency
striatum 1
SLC6A3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Dopamine 248 100.00 Very High Very High Very High
monoamine 11 100.00 Very High Very High Very High
noradrenaline 4 100.00 Very High Very High Very High
insula 2 92.88 High High
midbrain 2 89.28 High High
imagery 25 89.08 High High
Thalamus 15 88.76 High High
Neurotransmitter 31 88.40 High High
Eae 8 87.76 High High
Anterior cingulate 5 86.00 High High
Disease Link Frequency Relevance Heat
Sleep Disorders 98 96.52 Very High Very High Very High
Urological Neuroanatomy 4 84.36 Quite High
Anxiety Disorder 18 81.32 Quite High
Cognitive Disorder 52 65.80 Quite High
Headache 4 55.68 Quite High
Anxiety 2 54.88 Quite High
Heart Rate Under Development 3 53.84 Quite High
Movement Disorders 1 50.72 Quite High
Attention Deficit Hyperactivity Disorder 91 50.00 Quite Low
Disease 33 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
At low dose, their main effect is to release dopamine – and to a lesser extent noradrenaline – through reverse efflux via monoaminergic transporters, the dopamine transporter (DAT) and the norepinephrine transporter (NET).
Localization (release) of DAT associated with dopamine, noradrenaline and monoamine
1) Confidence 0.68 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2526380 Disease Relevance 0.81 Pain Relevance 0.60
DAT-BOLD correlation
Localization (correlation) of DAT
2) Confidence 0.64 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2699543 Disease Relevance 0.07 Pain Relevance 0.36
Seeman and Madras [9] suggested that methylphenidate (MP) blocks the dopamine transporter (DAT), resulting in increased extracellular DA, activating autoreceptors and leading to an attenuation of DA release in response to phasic DA firing.
Localization (methylphenidate) of DAT associated with dopamine
3) Confidence 0.39 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2289834 Disease Relevance 0.08 Pain Relevance 0.66
Seeman and Madras [9] suggested that methylphenidate (MP) blocks the dopamine transporter (DAT), resulting in increased extracellular DA, activating autoreceptors and leading to an attenuation of DA release in response to phasic DA firing.
Localization (methylphenidate) of dopamine transporter associated with dopamine
4) Confidence 0.39 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2289834 Disease Relevance 0.08 Pain Relevance 0.66
The latter recent result demonstrated that estrogenic effects on the DAT (reversal of the transporter to cause efflux) are mainly mediated via ER?
Localization (reversal) of DAT
5) Confidence 0.21 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971739 Disease Relevance 0.08 Pain Relevance 0.09
There are also sex differences in the expression levels and localization of DAT; females express higher DAT levels in the striatum than men,142 although men experience higher amplification of amphetamine-stimulated striatal dopamine release,143 perhaps because of their lower baseline levels due to lower endogenous estrogen levels.
Localization (localization) of DAT in striatum associated with dopamine
6) Confidence 0.21 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971739 Disease Relevance 0 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox